DURHAM, N.C. – A software tool to automatically calculate how extensively bones have been infiltrated by prostate cancer is both accurate and speedy, capturing key prognostic information related to survival and the development of symptoms over time.
The software, called the automated bone scan index, was tested in a large, global multicenter study led by Duke Cancer Institute researchers. Findings from the phase 3 study were published May 17 in JAMA Oncology.
“This study describes major improvements over older techniques doctors used to measure bone metastases to predict survival and help guide treatments for patients with advanced prostate cancer,” said lead author Andrew Armstrong, M.D., associate professor of medicine and surgery and associate director of the Duke Cancer Institute’s Prostate and Urologic Cancer Center.
“It’s important to know how widespread metastatic disease is – both for patients to understand the likely course of their disease, and for doctors to determine the best potential treatments,” Armstrong said. “It is also a necessary point of reference in clinical trials, to understand whether investigational therapies are working and to quantify and predict possible outcomes.”
The current method to measure bone metastases includes a CT or MRI scan along with a nuclear medicine
Article originally posted at